[go: up one dir, main page]

CA2381008A1 - Composes fixant les recepteurs de melanocortine-4 et procedes d'utilisation de ces composes - Google Patents

Composes fixant les recepteurs de melanocortine-4 et procedes d'utilisation de ces composes Download PDF

Info

Publication number
CA2381008A1
CA2381008A1 CA002381008A CA2381008A CA2381008A1 CA 2381008 A1 CA2381008 A1 CA 2381008A1 CA 002381008 A CA002381008 A CA 002381008A CA 2381008 A CA2381008 A CA 2381008A CA 2381008 A1 CA2381008 A1 CA 2381008A1
Authority
CA
Canada
Prior art keywords
phenyl
tetrahydro
methoxy
pyrimidine
benzylsulfanyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002381008A
Other languages
English (en)
Inventor
Martin P. Maguire
Mingshi Dai
Tricia J. Vos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2381008A1 publication Critical patent/CA2381008A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Cette invention se rapporte à des composés fixant les récepteurs MC4-R, ces composés étant représentés par la formule: B-Z-E (I), où B représente une fraction d'ancrage, Z représente une fraction centrale et E représente une fraction interagissant avec les récepteurs MC4-R. Des procédés d'utilisation de ces composés pour traiter les maladies associées aux récepteurs MC4-R, telles que les troubles associés à la perte de poids, sont également décrits.
CA002381008A 1999-08-04 2000-08-04 Composes fixant les recepteurs de melanocortine-4 et procedes d'utilisation de ces composes Abandoned CA2381008A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14728899P 1999-08-04 1999-08-04
US60/147,288 1999-08-04
US22327700P 2000-08-03 2000-08-03
US60/223,277 2000-08-03
PCT/US2000/021327 WO2001010842A2 (fr) 1999-08-04 2000-08-04 Composes fixant les recepteurs de melanocortine-4 et procedes d'utilisation de ces composes

Publications (1)

Publication Number Publication Date
CA2381008A1 true CA2381008A1 (fr) 2001-02-15

Family

ID=26844785

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002381008A Abandoned CA2381008A1 (fr) 1999-08-04 2000-08-04 Composes fixant les recepteurs de melanocortine-4 et procedes d'utilisation de ces composes

Country Status (7)

Country Link
EP (1) EP1204645A2 (fr)
JP (1) JP2003528810A (fr)
AU (1) AU6621600A (fr)
BR (1) BR0012984A (fr)
CA (1) CA2381008A1 (fr)
MX (1) MXPA02001160A (fr)
WO (1) WO2001010842A2 (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064091A2 (fr) 2001-02-13 2002-08-22 Palatin Technologies, Inc. Metallopeptides de melanocortine pour le traitement de dysfonctions sexuelles
US6465467B1 (en) 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
CA2377369A1 (fr) 1999-06-04 2000-12-14 Merck & Co., Inc. Piperidines substituees en tant qu'agonistes du recepteur de melanocortine-4
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6699873B1 (en) 1999-08-04 2004-03-02 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US7375125B2 (en) * 1999-08-04 2008-05-20 Ore Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
AU4875301A (en) 2000-04-14 2001-10-30 Kureha Chemical Ind Co Ltd Nitrogenous compounds and antiviral drugs containing the same
DZ3415A1 (fr) * 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
EP1339677B1 (fr) * 2000-10-30 2006-01-04 Warner-Lambert Company LLC Ligands des recepteurs de serotonine aminoalkylpyrrolidine et compositions, leurs utilisations pharmaceutiques, et procedes pour leur synthese
CA2430951A1 (fr) * 2000-12-07 2002-06-13 Cv Therapeutics, Inc. Composes d'augmentation d'abca-1
EP1363890A4 (fr) * 2001-02-07 2009-06-10 Ore Pharmaceuticals Inc Composes de liaison au recepteur de la melanocortine-4 et procedes d'utilisation de tels composes
PT1385823E (pt) 2001-04-09 2007-01-31 Novartis Vaccines & Diagnostic Compostos de guanidino como agonistas do receptor de melanocortina-4 (r-mc4)
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7354923B2 (en) 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US7064139B2 (en) * 2001-10-29 2006-06-20 Uniroyal Chemical Company, Inc. Method for treating retroviral infections
JP2005519876A (ja) * 2001-11-27 2005-07-07 メルク　エンド　カムパニー　インコーポレーテッド ２−アミノキノリン化合物
CA2467337A1 (fr) 2001-12-21 2003-07-10 H. Lundbeck A/S Derives aminoindane utilises comme inhibiteurs de la capture de la serotonine et de la norepinephrine
US20030195187A1 (en) * 2002-02-04 2003-10-16 Chiron Corporation Guanidino compounds
WO2003068738A1 (fr) * 2002-02-11 2003-08-21 Neurocrine Biosciences, Inc. Derives de pyrrole utilises en tant que ligands de recepteurs de melanocortine
ATE434610T1 (de) 2002-03-13 2009-07-15 Euro Celtique Sa Aryl substituierte pyrimidine und deren verwendung
DE60333937D1 (de) 2002-05-23 2010-10-07 Novartis Vaccines & Diagnostic Substituierte quinazolinone verbindungen
JP2004067673A (ja) * 2002-06-11 2004-03-04 Sankyo Co Ltd 環状チオエーテル類の製造法及びその合成中間体
US7396930B2 (en) 2002-06-11 2008-07-08 Sankyo Company, Limited Process for producing cyclic thioether and synthetic intermediate thereof
AU2003242092A1 (en) * 2002-06-11 2003-12-22 Sankyo Company, Limited Process for producing cyclic thioether and synthetic intermediate thereof
GB2389581A (en) * 2002-06-12 2003-12-17 Viaxxel Biotech Gmbh Hydrogenated pyrimidines and their use as inhibitors of deoxyhypusine-synthase or hypusination of eIF-5A
AU2003248888A1 (en) 2002-07-09 2004-01-23 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
JP3714948B2 (ja) 2002-09-11 2005-11-09 呉羽化学工業株式会社 アミン化合物及びその用途
WO2004042351A2 (fr) * 2002-10-30 2004-05-21 Merck & Co., Inc. Modulateur piperidinyl-alpha-aminoamide de l'activite de recepteurs de la chimiokine
EP1590338B1 (fr) * 2002-12-04 2009-08-26 Ore Pharmaceuticals Inc. Modulateurs du recepteur de la melanocortine
FR2852957B1 (fr) * 2003-03-31 2005-06-10 Sod Conseils Rech Applic Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
HRP20080478T3 (hr) 2003-04-04 2009-02-28 H. Lundbeck A/S Derivati 4-(2-fenilsulfanil-fenil)-piperidina kaoinhibitori ponovne pohrane serotonina
DE10316081A1 (de) * 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
AU2004249120B2 (en) 2003-05-23 2008-07-24 Glaxosmithkline Guanidino-substituted quinazolinone compounds as MC4-R agonists
AU2004293012A1 (en) 2003-11-19 2005-06-09 Rustum S. Boyce Quinazolinone compounds with reduced bioaccumulation
FR2862971B1 (fr) * 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
ATE396970T1 (de) 2003-12-23 2008-06-15 Lundbeck & Co As H 2-(1h-indolylsulfanyl)-benzylaminderivate als ssri
CA2558600C (fr) 2004-03-10 2013-07-09 Kureha Corporation Compose trialkyl-amine substitue avec activite antivirale basee sur un antagonisme contre les recepteurs chimiokines cxcr4
AR052308A1 (es) 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
US20070021433A1 (en) * 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
AR054393A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
TW200819426A (en) 2006-08-31 2008-05-01 Lundbeck & Co As H Novel indane compounds
EP2103614A1 (fr) * 2008-03-18 2009-09-23 Santhera Pharmaceuticals (Schweiz) AG Dérivés d'imidazopyrimidine, d'imidazopyrazine et d' imidazopyridazine substitués en tant que modulateur de récepteur de la mélanocortine-4
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
PT2424843E (pt) 2009-04-30 2014-06-02 Novartis Ag Derivados de imidazol e seu uso como moduladores de quinases dependentes de ciclina
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
PH12013501686A1 (en) 2011-02-25 2017-10-25 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
CA2880901A1 (fr) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Composes tricycliques antidiabetiques
US10059671B2 (en) 2013-02-04 2018-08-28 Prexton Therapeutics Sa Positive allosteric modulators of mGluR3
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
WO2014139388A1 (fr) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
WO2015051496A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
WO2016056606A1 (fr) * 2014-10-07 2016-04-14 国立大学法人京都大学 Dérivé benzoisothiazolopyrimidine et sel de ce dernier, et inhibiteur d'infection virale et médicament
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (fr) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Composés de spirochromane antidiabétiques
US11014927B2 (en) 2017-03-20 2021-05-25 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
CN108084109A (zh) * 2017-12-21 2018-05-29 南京工业大学 一种2，5－二取代－1．3．4－噁二唑的合成方法
US11666888B2 (en) 2018-02-05 2023-06-06 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
US20200115389A1 (en) 2018-09-18 2020-04-16 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
CN113423711B (zh) * 2018-10-01 2024-03-15 建新公司 作为udp糖基转移酶抑制剂的噻吩并[3,2-b]吡啶衍生物及其使用方法
EP4031132A4 (fr) 2019-09-19 2023-09-13 Forma Therapeutics, Inc. Activation de la pyruvate kinase r
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
AR121356A1 (es) 2020-02-18 2022-05-11 Gilead Sciences Inc Compuestos antivirales
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
EP4323362B1 (fr) 2021-04-16 2025-05-07 Gilead Sciences, Inc. Procédés de préparation de carbanucléosides à l'aide d'amides
CA3228162A1 (fr) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Composes phospholipidiques et leurs procedes de production et d'utilisation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3594380A (en) * 1969-02-18 1971-07-20 American Home Prod Isoquinolin-1(2h)-ones
DE2219841A1 (de) * 1972-04-22 1973-10-25 Basf Ag Verfahren zur herstellung von 2-(oalkylthiophenyl)-1,3-diazacycloalkenhydrohalogeniden
US4122263A (en) * 1973-04-11 1978-10-24 Basf Aktiengesellschaft Production of 2-(o-alkylthiophenyl)-1,3-diazocycloalkene hydrohalides
DE3046366A1 (de) * 1980-12-09 1982-07-08 Bayer Ag, 5090 Leverkusen Tricyclische cytosinderivate zur verwendung in arzneimitteln und verfahren zu ihrer herstellung
GB8619971D0 (en) * 1986-08-15 1986-09-24 Fujisawa Pharmaceutical Co Imidazole compounds
JPS63253073A (ja) * 1987-04-08 1988-10-20 Taisho Pharmaceut Co Ltd ２−フエニルベンズイミダゾ−ル誘導体
ZA923283B (en) * 1991-05-29 1993-01-27 Akzo Nv Phenoxyphenyl derivatives
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
JPH09176871A (ja) * 1995-12-25 1997-07-08 Tamura Kaken Kk 水溶性プリフラックス、プリント回路基板及びプリント回路基板の金属の表面処理方法
US5932779A (en) * 1996-06-10 1999-08-03 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
ATE502041T1 (de) * 1997-04-15 2011-04-15 Csir Nicht-therapeutische methode zur appetitunterdrückung
ATE239013T1 (de) * 1997-12-19 2003-05-15 Lilly Co Eli Hypoglykamische imidazoline derivate
AU742425B2 (en) * 1998-06-11 2002-01-03 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists

Also Published As

Publication number Publication date
WO2001010842A3 (fr) 2001-08-16
AU6621600A (en) 2001-03-05
MXPA02001160A (es) 2002-07-02
JP2003528810A (ja) 2003-09-30
BR0012984A (pt) 2002-07-16
EP1204645A2 (fr) 2002-05-15
WO2001010842A2 (fr) 2001-02-15

Similar Documents

Publication Publication Date Title
CA2381008A1 (fr) Composes fixant les recepteurs de melanocortine-4 et procedes d'utilisation de ces composes
US6699873B1 (en) Melanocortin-4 receptor binding compounds and methods of use thereof
US7375125B2 (en) Melanocortin-4 receptor binding compounds and methods of use thereof
EP1363890A2 (fr) Composes de liaison au recepteur de la melanocortine-4 et procedes d'utilisation de tels composes
DE60118564T2 (de) Propan-1,3-dion-derivate
CA2543707A1 (fr) Composes heterocycliques accoles contenant de l'azote
PL129174B1 (en) Process for preparing novel derivatives of piperidine
JP2006509014A (ja) メラノコルチンレセプターの調節因子
PT98768B (pt) Processo de preparacao de derivados de piperazinilo e de composicoes farmaceuticas que os contem
JPH0873439A (ja) １−ベンジル−１，３−ジヒドロ−２ｈ−ベンズイミダゾール−２−オン誘導体、これらの調製およびこれらを含有する薬学的組成物
US6221871B1 (en) Certain aminomethyl biphenyl, aminomethyl phenyl pyridine and aminomethyl phenyl pyrimidine derivatives; novel dopamine receptor subtype selective ligands
DE69824722T2 (de) Benzimidazol-Derivat
US4358456A (en) Antipsychotic piperidinomethyl-indole derivatives
AU2005313311A1 (en) Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
EP1057818A1 (fr) DERIVES DE PHENYLPIPERAZINE UTILISES COMME ANTAGONISTES DE L'INTEGRINE ALPHAvBETA3
US4588725A (en) 2-piperazinyl-quinazoline derivatives and pharmaceutical compositions containing them
US3721739A (en) Imidazolidinone derivatives in a composition and method for producing c.n.s.depressant effects
US20040039045A1 (en) (2-azabicyclo[2.2.1]hept-7yl) methanol derivatives as nicotinic acetylcholine receptor agonists
AU2004202804B2 (en) Melanocortin-4 Receptor Binding Compounds and Methods of use thereof
US6436941B2 (en) 5,6-dihydro-napth[1,2-d]-imidazole, napth[1,2-d]imidazole, and chromane[3,4-d]imidazole derivatives
US5773616A (en) Certain bridged 4-phenyl-2-aminomethylimidazoles; new dopamine receptor subtype specific ligands
US5541179A (en) Tropon-2-one piperazine carboxamides as serotonergic agents
WO1995030658A1 (fr) Derives de benzimidazoles dimeres, leur preparation et leur utilisation comme agents dopaminergiques hautement selectifs vis-a-vis des recepteurs d3 a la dopamine
JP2002205987A (ja) アシルアミノシクロプロパン誘導体
DE2820718A1 (de) Neue 5-phenyl-1h-3-benzazepine, ihre herstellung und verwendung

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead